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The aim of this study was to investigate the beneﬁt of weekly epirubicin in the treatment of metastatic hormone-resistant
prostate cancer. One hundred and forty-eight patients with metastatic hormone-resistant prostate cancer received weekly 30-
min intravenous infusions of epirubicin 30 mg m
2 of body surface area. The primary end-point was palliative response, deﬁned
as a reduction in pain intensity and an improvement in performance status. The secondary end-points were the duration of
the palliative response, quality of life and survival. Fifty-seven (44%) of the 131 evaluable patients met the primary criterion of
palliative response after six treatment cycles and 73 (56%) after 12 cycles; the median duration of the response was 9 months
(range 1–11). The median global quality of life improved in 52% of the patients after six cycles and in 68% after 12 cycles.
The 12- and 18-month survival rates were respectively 56 and 31%, with a median survival of 13+ months (range 1–36). The
treatment was well tolerated: grade 3 neutropenia was observed in 8% of the patients, grade 3 anaemia in 7%, and grade 3
thrombocytopenia in 3%. None of the patients developed grade 4 toxicity or congestive heart failure. Weekly epirubicin
chemotherapy can lead to a rapid and lasting palliative result in patients with metastatic HRPC, and have a positive effect on
the quality of life and survival.
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Prostate carcinoma remains the most common cancer in males.
Both surgery and radiation therapy are potentially curative
provided that the tumour is conﬁned to the prostate itself but, if
the lymph nodes are involved, the possibility of dissemination is
high. Hormonal therapy remains a standard and effective systemic
approach to disseminated disease (Catalona, 1994), but it is unfor-
tunately successful in only 70–80% of patients and the median
duration of response is no longer than 12–24 months (Gittes,
1991). The median survival of men with hormone refractory
disease has increased over the last few years from 9–12 to 15–
20 months, more as a result of the earlier detection of androgen-
insensitive disease by means of PSA levels rather than symptoms
(Daneshgari and Crawford, 1993; Hussain et al, 1994; Knox and
Moore, 2001).
The role of chemotherapy in the treatment of hormone-resistant
prostate carcinoma (HRPC) has not yet been established. Most
previous studies have found little evidence of anti-tumour activity,
with response rates of less than 10% for single chemotherapeutic
agents and similar results for combination therapies (Eisenberger
et al, 1985; Millikan, 1999). However, more recent studies with
mitoxantrone, docetaxel and estramustine have shown a response
(Tannock et al, 1996; Savarese et al, 2001). It is difﬁcult to assess
the effectiveness of chemotherapeutic agents in the treatment of
metastatic prostate cancer because the patients often do not have
measurable disease (Coleman, 1998). One of the biggest problems
is monitoring the response in bone, which is the only site of metas-
tases in most patients. Various tumour and bone turnover markers
can be useful in assessing true changes in bone lesions and, in this
setting, one of our recent studies showed that urinary calcium
excretion was the most useful marker for monitoring clinical
response (Francini et al, 2001).
Doxorubicin has shown some activity in the treatment of HRPC
patients (Torti et al, 1983; Scher et al, 1984), and we have
previously reported the satisfactory effectiveness of the doxorubicin
analogue epirubicin which, at equipotent doses, is associated with
quantitatively less severe toxicities than its parent compound
(Francini et al, 1993). However, our results were based on standard
National Prostatic Cancer Project (NPCP) criteria that no longer
seem to be satisfactory for evaluating response (Slack and Murphy,
1984).
The present extended study coordinated by the University of
Siena’s Oncopharmacology Centre was performed in order to verify
the palliative response of epirubicin-based chemotherapy on the
basis of validated criteria such as pain and performance status.
PATIENTS AND METHODS
Eligibility criteria
The study involved patients with histologically conﬁrmed measur-
able or evaluable metastatic prostatic carcinoma that had
progressed during hormonal therapy. The patients were admitted
C
l
i
n
i
c
a
l
Received 28 March 2002; revised 11 July 2002; accepted 15 July 2002
*Correspondence: G Francini; Medical Oncology Division, Institute of Inter-
nal Medicine, Siena University, Viale Bracci 11, 53100 Siena, Italy
E-mail: francini@unisi.it
British Journal of Cancer (2002) 87, 720–725
ã 2002 Cancer Research UK All rights reserved 0007–0920/02 $25.00
www.bjcancer.comto the chemotherapy protocol provided that they met at least one
of the following criteria: an increase in PSA level of 550% in
comparison with baseline on two successive occasions separated
by at least 2 weeks; new metastatic lesions revealed by a bone scan;
an increase of more than 25% in a bidimensionally measurable
tumour mass. The patients treated with LH-RH agonists had to
continue their primary androgen ablation therapy, and were
required to have serum testosterone levels 530 ng ml
71 before
study entry. Anti-androgens had to be stopped 4–6 weeks before
the use of chemotherapy in order to allow the withdrawal to
become effective. All of the patients had symptoms that included
pain. All of the patients had to have a Karnofsky performance
status (KPS) of 550, and adequate haematological (leukocytes
53000 ml
71; haemoglobin 58gd L
71, platelets 5100000 ml
71),
renal (serum creatinine 42.0 mg dl
71), and hepatic function
(serum bilirubin 42.0 mg dl
71). Patients with widespread bone
metastases or platelet counts of between 50000 and 100000 ml
71
were also included in the study. The exclusion criteria were
previous chemotherapy, congestive heart failure, a recent myocar-
dial infarction, or other previous malignant diseases except basal
cell carcinoma or squamous cell carcinoma of the skin. All of
the patients gave their informed consent, and the protocol was
approved by the Ethics Committee of the Siena University.
Assessment of response and quality of life
The pretreatment evaluation included a complete physical exami-
nation and the determination of a baseline KPS score. The
primary end-point was a palliative response, which was deﬁned
as a 2-point reduction in the 6-point present pain intensity scale
of the McGill-Melzack Pain Questionnaire (or the complete disap-
pearance of pain if the initial score was 1+), and an improvement
in KPS of one 10-point category from baseline (Melzack, 1975).
These results had to be maintained at two consecutive evaluations
made at least 3 weeks apart and without any increase in analgesic
consumption. The pain scale has verbal descriptors (0=no pain,
1=mild pain, 2=discomforting pain, 3=distressing pain, 4=horrible
pain, and 5=excruciating pain), and the patients were asked to clas-
sify the average pain level during the previous 24 h. We used a
translated form of the McGill Melzack Questionnaire to which
the ‘reconstruction-based methodology’ has been applied (De
Benedittis et al, 1988).
The other end-points of the study were the duration of the
palliative response (as deﬁned by the primary end-point), a
450% decrease in PSA levels compared with baseline on two
successive occasions separated by a period of at least 2 weeks, qual-
ity of life and survival. Progression was deﬁned as an increase in
the present pain intensity scale of 41 point above the nadir or
a 425% increase in analgesic consumption in comparison with
baseline, each recorded at two consecutive visits; unequivocal
evidence of new lesions, radiological progression, or the need for
radiation therapy also constituted disease progression. Analgesic
consumption was based on the average daily quantities taken by
the patient during the previous week.
PSA progression was deﬁned as two consecutive increases in
serum PSA concentrations to more than 50% above baseline or
nadir levels. The patients with stable serum PSA concentrations
included those without PSA progression but with a less than
50% decrease in baseline levels.
In order to assess the effects of disease and treatment on the
patients’ health-related quality of life, they were asked to complete
the European Organization for Research and Treatment of Cancer
(EORTC) core questionnaire (EORTC/QLQ-C30) at trial entry and
then every 3 weeks. This questionnaire, which has been translated
and validated in 38 languages including Italian, consists of 30 ordi-
nal scale items that include multi-item domains for physical
function, emotional function, social function, pain, and the global
quality of life, and individual items including fatigue, appetite and
constipation (Aaronson et al, 1993).
The laboratory studies included blood and platelet counts and a
comprehensive screening proﬁle (alkaline phosphatase, blood urea
nitrogen, creatinine, calcium, phosphorus, uric acid, total protein,
albumin, total bilirubin and electrolyte levels) at baseline and every
3 weeks. Serum PSA, serum calcium, the urinary calcium/creatinine
ratio (UCa/Cr), serum phosphate, the urinary phosphate/creatinine
ratio, serum bone alkaline phosphatase, serum procollagen type I
carboxy-terminal pro-peptide, the urinary hydroxyproline/creatinine
ratio, and serum carboxy-terminal telopeptide of collagen type I
were all measured using standard methods at baseline and after six
and 12 chemotherapy cycles (Francini et al, 1988, 1992). The patients
underwent a weekly complete blood cell count before chemotherapy.
The imaging studies included an abdominal and pelvic CT scan or
magnetic resonance imaging, a bone scan and chest radiograph.
All measurable disease was re-evaluated at 12-week intervals, and
radionuclide bone scans were repeated every 12 weeks. In all cases,
a baseline ECG was obtained, and a further cardiac work-up was
performed if indicated. The palliative response and quality of life
data were reviewed by an independent external consultant.
Treatment plan
Treatment consisted of 30-min intravenous infusions of epirubicin
30 mg m
2 of body-surface area, which were given at 1-week inter-
vals if serum WBC levels were 43000 ml
71, granulocytes
41500 ml
71, and platelets 4100000 ml
71. The platelet counts of
the patients enrolled with levels of between 50000 and
100000 ml
71 had to normalise during the ﬁrst three chemotherapy
cycles; if not, the treatment was discontinued. Chemotherapy was
given until progression or the onset of severe toxicity. In order
to minimise the probability of cardiac toxicity, it was recom-
mended that the patients still responding after a cumulative
epirubicin dose of 720 mg m
72 continue treatment with the best
supportive care alone. Metoclopramide was used as antiemetic
medication; dexamethasone or other steroids were not used.
The patients continued to take analgesic medication at doses
adjusted in order to provide optimal pain control. Bisphosphonates
were not used. The chemotherapy was initally administered in
hospital to the patients whose KPS was between 60 and 50%; if
their performance status improved during treatment, it was subse-
quently administered on an outpatient basis.
Treatment-related adverse events
These were assessed weekly using World Health Organisation
(WHO) criteria (Miller et al, 1981). The treatment was interrupted
at the ﬁrst occurrence of grade II toxicity and resumed at the same
dose after resolution to grade I or better, with prophylaxis being
given when possible. In the case of grade III or IV toxicity, the
treatment was interrupted and a maximum of 3 weeks were
allowed for recovery, after which the patients were withdrawn from
the study. Anaemia was treated as clinically indicated; nausea and
vomiting were treated symptomatically. Haematopoietic growth
factors were not routinely used but given only when neutrophil
counts fell below 1000 m
3 and continued until complete haemato-
logical recovery.
Statistics
In accordance with Simon’s two-stage phase II design, a sample
size of 110 patients was required, assuming a palliative result of
approximately 30% for other treatment modalities and a target
activity level of interest of 45%, with an a of 0.05 and a b of
0.90. It was planned to enrol a further 20 patients in the expecta-
tion of at least 10–15% of unevaluable cases.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(7), 720–725Differences in the QL measures between baseline and the subse-
quent treatment cycles were assessed using a paired t-test. The
duration of survival was measured from the date of ﬁrst treatment
to the date of death or last follow-up.
RESULTS
Between February 1996 and June 2001, 148 patients with HRPC
were enrolled; their median age was 67 years (range 49–75). The
initial KPS was 90% in 27 patients, between 80% and 70% in
96, and between 60% and 50% in 25. One hundred and forty-
two patients had bone metastases; the other six (4%) had other
than bone metastases and measurable disease (Table 1).
Palliative response was evaluable in 131 patients (seven patients
received only one or two treatment cycles, three refused to continue
after two treatment cycles, two died of causes other than cancer
before the fourth treatment cycle, and ﬁve were excluded because
of corticosteroid use). The 131 evaluable patients received a total
of 1765 cycles (median per patient 13 cycles; range 3–24). A pallia-
tive response was observed in 57 patients (44%) after six treatment
cycles and 73 (56%) after 12 cycles (Table 2). The median response
duration was 9 months (range 1–11). Most of the patients experi-
enced a rapid and progressive decrease in pain intensity and
analgesic medication during the ﬁrst three treatment cycles, as well
as an improvement in KPS. After 12 treatment cycles, pain intensity
had stabilised in 42 patients without any increase in analgesic
consumption for at least 3 weeks after the beginning of chemother-
apy, whereas 16 patients experienced progressive disease as shown by
worsening pain or KPS and/or new bone lesions. The disease stabi-
lised in four of the six patients with measurable lesions, and
progressed in the remaining two. On the basis of the change in
PSA levels, 32 (24%) of the 131 evaluable patients showed a PSA
response, 54 (41%) stable disease, and 45 (35%) progression. Among
the 73 patients who achieved a palliative response after 12 treatment
cycles, UCa/Cr increased by 450% in 27 (37%) and PSA decreased
by 450% in 22 (30%) (P=0.4; w
2-test); among the 58 non-respon-
ders, UCa/Cr increased by 450% in only two (3%) and PSA
decreased by 450% in 10 (17%) (P=0.03; w
2-test) (Figure 1).
Quality of life and survival
Baseline QLQ-C30 data were available for 127 patients (a compli-
ance rate of 86%); the remaining patients were excluded from the
further serial analyses. For ease of interpretation, all of the scale
and item scores were linearly transformed to a 0–100 scale. The
baseline scores suggested that the patients were highly sympto-
matic. Compliance with QL assessment decreased to 94 patients
(63%) after six treatment cycles and 77 (52%) after 12 cycles.
The main reasons for non-compliance were disease progression,
unacceptably completed forms and/or death. Figure 2 shows the
mean changes in the scores from baseline to cycles 6 and 12. By
cycle 12, there were signiﬁcant differences from baseline in physical
and emotional function, global QL and pain scores (P50.01,
P50.01, P50.005, P50.001, respectively). The mean global QL
improved in 52% of the patients after six treatment cycles and
in 68% after 12 cycles. A total of 128 patients had died as of
December 2001. The survival rate was 56% after 12 months and
31% after 18 months, with a median survival of 13+ months (range
1–36) (Figure 3).
Toxicity
The chemotherapy was well tolerated and there were no treatment-
related deaths. The majority of patients continued to work full
time, with treatment having a minimal impact on normal daily
activities. Neutropenia and anaemia were the most frequent side
effects, but were grade I or II in most cases; grade III neutropenia
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Table 1 Main characteristics of patients
Enrolled patients 148
Evaluable patients 131
Median age (range): years 67 (49–75)
Karnofsky Performance Status
90% 27
80% 36
70% 60
60% 18
50% 7
Sites of metastasis
Bone 142
Lymph nodes 4
Visceral 1
Other 1
PSA (mgl
71)
Median 148
Range 41–526
Prior treatment
LH-RH agonists only 65
Antiandrogens only 22
Total androgen blockade 61
Duration of response to hormonal treatment (months)
Median 15
Range 5–37
Present pain intensity
00
13 3
27 6
33 1
48
50
Overall quality of life (EORTC QLQ-C30)
a
Mean score 41
Range 31–56
a0=very poor; 100=excellent.
Table 2 Palliative response in 131 evaluable HRPC patients treated with
weekly epirubicin
Number of patients (%)
Response Cycle 6 Cycle 12
Responders 57 (44) 73 (56)
Stable disease 61 (47) 42 (32)
Progressive disease 13 (9) 16 (12)
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responders
(n = 73)
non-responders
(n = 58)
37%
30%
3%
17%
P<0.05
UCa/Cr>50%
PSA<50%
Figure 1 Per cent change in UCa/Cr and PSA in responders and non-re-
sponders, after 12 treatment cycles. P50.05 (X
2 -test), signiﬁcantly differ-
ent between PSA and UCa/Cr in non-responding patients; in parentheses,
n=number of patients.
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British Journal of Cancer (2002) 87(7), 720–725 ã 2002 Cancer Research UKoccurred in 8% of the patients and grade III anaemia in 7%. Grade
III thrombocytopenia occurred in 3% of the patients. None of the
patients experienced grade IV toxicity. The administration of at
least one treatment cycle was delayed by 1 week in 36 patients:
the reasons for the delays were haematological in 29 cases (22%)
and non-haematological (stomatitis, nausea) in seven (5%). Sixteen
patients showed an improvement in anaemia and platelet counts
after 1–3 treatment cycles. Twenty-four patients, who received
cumulative doses of 720 mg m
2, did not develop clinical congestive
heart failure, but two developed atrial ﬁbrillation that was medi-
cally controlled without further cardiac complications. Perfor-
mance status also improved in many of the patients with an initial
KPS of between 60 and 50%, so that the subsequent cycles could be
administered on an outpatient basis; a total of 93% of all of the
chemotherapy cycles were given in this manner.
DISCUSSION
Most cytotoxic drugs, alone or in combination, have usually led to
low response rates and a brief median survival in patients with
HRPC. More recently, taxanes and new drug combinations have
demonstrated some activity in this disease, partially due to a recon-
sideration of end points such as QL parameters (Tannock et al,
1996; Picus and Schultz, 1999; Kelly et al, 2001).
The results of this study provide evidence of the palliative effect
of weekly epirubicin chemotherapy in 131 evaluable patients with
HRPC. A palliative response (deﬁned as an improvement in the
pain index and performance status) was observed in 44% of the
patients after six treatment cycles, and 56% after 12 cycles (Table
2). This high response rate may be related to the real anti-tumour
activity of epirubicin, and/or the baseline characteristics of the
patients. It is known that some prognostic factors, such as a long
period of responsiveness to previous hormonal therapy, a good
performance status and a limited extension of bone metastases
are usually correlated with a more favourable disease outcome
(Fossa et al, 1992; Hussain et al, 1994). About 85% of our patient
population had responded to previous hormonal treatment for
412 months, but most of them had widespread bone metastases
and a poor performance status. A detailed statistical study of prog-
nostic factors in HRPC will be presented in the future.
Our results correlated with changes in bone and tumoral
markers: the concordance of an increase in UCa/Cr in responders
was not signiﬁcantly different from the decrease in PSA, whereas
the concordance of these two indices in non-responders was statis-
tically signiﬁcant (Figure 1). This ﬁnding suggests that the change
in UCa/Cr agrees better with a palliative response than the change
in PSA. The correlation between the changes in UCa/Cr and
response or non-response is supported by one of our previous
studies showing that UCa/Cr is the best marker for monitoring
bone metastases from prostate cancer (Francini et al, 2001).
The median duration of the palliative response was about 10
months, which is similar to that recently observed with the use
of mitoxantrone + prednisone or taxotere, and longer than that
found with prednisone alone, vinorelbine or paclitaxel (Tannock
et al, 1996; Fields-Jones et al, 1999; Trivedi et al, 2000; Savarese
et al, 2001). The palliative response was accompanied by an
improvement in a number of the quality of life dimensions, parti-
cularly a reduction in pain and an improvement in functional
scales. It has been shown that pain and reduced physical function
are the most frequent complaints in HRPC patients, and so
improving these dimensions represents an important treatment
goal (Moore et al, 1994). Moreover, the improvement in perfor-
mance status during treatment in many patients with an initial
KPS of between 60 and 50% led to them being treated on an
outpatient basis after 2–6 cycles received as in-patients. However,
given that compliance with QL data assessment was low, it is difﬁ-
cult to draw strong conclusions from the QL data.
The proposed weekly epirubicin chemotherapy was well toler-
ated and did not cause any unexpected toxicities. The main
toxicity was mild myelosuppression, but decreased haemoglobin
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Role function
Emotional function
Cognitive function
Social function
Global QL
Fatigue
Nausea/vomiting
Pain
Dyspnoea
Sleeping difficulty
Appetite loss
Constipation
Diarrhoea
-30 -20 -10 0 10 20 30
6th cycle
12th cycle
Worse Better
Figure 2 Mean changes in QLQ-C30 scores.
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Figure 3 Overall survival of 148 HRPC patients treated with weekly
epirubicin.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(7), 720–725and platelet levels may reﬂect the metastatic invasion of bone
marrow or uremic marrow suppression, and sometimes urinary
blood losses (Berry et al, 1979). It is worth noting that 16 patients
showed an improvement in bone marrow reserves, with increased
haemoglobin levels and platelet counts after 1–3 treatment cycles,
a ﬁnding which suggests that epirubicin is active against the
neoplastic invasion of bone marrow from prostate cancer. No case
of congestive heart failure was observed probably because weekly
anthracycline schedules are less cardiotoxic than 3-weekly adminis-
trations, and are well tolerated even in elderly populations such as
that represented by prostate cancer patients (Chlebowski et al,
1980). Another factor contributing to the absence of severe cardi-
otoxicity was the planned discontinuation of chemotherapy at the
cumulative dose of 720 mg m
72. In order to increase efﬁcacy,
higher doses of epirubicin (100 mg m
72 i.v. every 3 weeks) have
been tested, with a 24% partial response rate based on WHO
criteria (Brausi et al, 1995). Interesting results have been reported
with epirubicin 100 mg m
72 every 3 weeks plus estramustine
phosphate (54% of the patients achieved a 550% reduction in
PSA); however, cardiovascular toxicity requiring hospitalisation
and grade 3–4 myelotoxicity occurred (Hernes et al, 1997). Our
results suggest that reducing the individual doses of epirubicin
may be preferable in clinical use and allow prolonged periods of
treatment in HRPC.
The median survival of our study population (13+ months) was
slightly better than that found in most series (8–10 months) trea-
ted with other cytotoxic drugs or placebo (Tannock et al, 1996;
Heidenreich et al, 2001; Kelly et al, 2001). Although ours was
not a randomised trial, it is possible that an active and safe
chemotherapy such as weekly epirubicin may prolong survival with
a relatively good quality of life in HRPC patients.
In conclusion, weekly epirubicin chemotherapy can lead to a
rapid and lasting palliative result, and have a positive effect on
the quality of life and duration of survival, in patients with meta-
static HRPC. It is also worth noting that, even in this advanced
disease stage, weekly epirubicin could be administered on an
outpatient basis with mild toxicity.
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